Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Conference

Tuesday 27 March 2007
New Data Regarding Repeat Treatments of SIR-Spheres® Microspheres in Patients with Advanced Liver Tumors to be Included at Annual Meeting

LAKE FOREST, Ill. (March 27, 2007) – Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 43rd Annual American Society of Clinical Oncology (ASCO) conference. The meeting, to be held June 1-5 at the McCormick Place in Chicago, Ill., is considered the premier educational and scientific event in the oncology community. Sirtex manufactures SIR- Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has spread to the liver.1

In addition to the exhibition, new data regarding repeat treatments of SIR-Spheres microspheres will be included in the program. The paper authored by Andrew Kennedy, M.D., F.A.C.R.O, co-medical director of Wake Radiology Oncology in Cary, N.C., examined safety and patient selection regarding repeat microsphere radioembolization for hepatic malignancies. As patients live longer with hepatic tumors, a growing number of them require retreatment. According to Kennedy, with proper patient selection, repeat radiation to the liver with SIR-Spheres microspheres is safe and no dosing adjustments are needed.

“Sirtex is proud to support ASCO and its mission to improve cancer care and prevention and ensure that all cancer patients receive care of the highest quality,” says Nat Geissel, CEO, Sirtex Medical Inc. “We believe it is imperative that Sirtex continues to participate in meetings such as this to allow physicians the opportunity to learn about the latest advances and research regarding SIR-Spheres microspheres. We are able to speak directly with physicians and provide information that will ultimately help improve the level of care we are able to offer patients with advanced liver disease.”

Sirtex’s SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. According to a paper in the International Journal of Radiation Oncology Biology Physics, the use of SIR-Spheres microspheres in patient responders resulted in a median survival rate of 10.5 months from treatment.

Approximately 90 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 86 medical centers. The minimally invasive procedure is performed on an outpatient basis with minor side effects.

Sirtex Medical Inc.’s SIR-Spheres® microspheres are indicated for the treatment of non- resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer reviewed literature is different from the approved USA labeling for SIR-Spheres.

About Sirtex

SIR-Spheres microspheres were developed in the 1980s in Australia and were approved by the FDA in March 2002.  Sirtex has obtained regulatory approval to market SIR- Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit

SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd


Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



Now leaving

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.